dorsaVi (ASX: DVL) has commenced a feasibility study to incorporate blockchain technology and enhance the security of data on its core motion analysis platform.
The study aims to determine how an encrypted, immutable and tamper-proof solution could improve data safety, storage security and privacy controls for the company’s enterprise clients in healthcare and workplace contexts.
It will focus on leveraging advanced consensus mechanisms such as proof-of-stake and directed acyclic graphs, which offer energy-efficient scalability and security tailored to the needs of mobile health data applications.
Chief executive officer Dr Andrew Ronchi said the exploration of blockchain technology was a natural progression for dorsaVi.
“Our enterprise clients already demand the highest levels of data security, privacy and compliance and we believe blockchain could help us further meet and exceed those expectations and redefine how sensitive health data is managed, shared and secured,” he said.
“Embarking on this study demonstrates our commitment to ensuring our platform is prepared for future advances in motion analysis and data management and that we continue to deliver unmatched value to our clients and shareholders.”
dorsaVi’s core motion analysis technology platform includes one of the only wearable sensors on the market approved by the US Food and Drug Administration.
The platform currently supports millions of data transfers annually, capturing over 10,000 data points per session and including joint angles, muscle activity, gait parameters and postural alignment.
The sensors continuously track movement patterns with real-time data syncing for immediate analysis and long-term monitoring.
The integration of blockchain technology is expected to further strengthen the platform by helping ensure data remains compliant with regulatory standards while enhancing accuracy, security and scalability.
Additionally, it could allow dorsaVi’s platform to incorporate future advancements in artificial intelligence and wearable Internet of Things technologies.
This would enhance the platform’s versatility across the clinical care, workplace safety and elite sports markets.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。